Targeting antigens to dendritic cells in vivo

被引：96
作者：
Tacken, Paul J. [1 ]
Torensma, Ruurd [1 ]
Figdor, Carl G. [1 ]
机构：
[1] Radboud Univ Nijmegen, Nijmegen Med Ctr, Nijmegen Ctr Mol Life Sci, Dept Tumor Immunol, NL-6500 HB Nijmegen, Netherlands
来源：
IMMUNOBIOLOGY | 2006年 / 211卷 / 6-8期
关键词：
adenovirus; antigen; cross-presentation; dendritic cell; liposome; targeting;
D O I：
10.1016/j.imbio.2006.05.021
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Dendritic cells (DCs) play a key role in antigen-specific immune regulation. DCs take up and process antigens and present these as peptides through MHC molecules to T cells. Recent pre-clinical and clinical studies have exploited DCs as a means to improve vaccine efficiency. In these studies, monocyte-derived autologous DCs are loaded ex vivo with antigens and re-administered to the patient. These tailor-made vaccines are costly and labor intensive, and therefore less suitable for large-scale immunization programs. As a next step in the development of DC vaccines, it is proposed to load DCs with antigens in vivo. Drug delivery systems harboring antigens have been targeted to DCs via specific surface receptors preferentially expressed by DCs, resulting in priming of humoral and cellular immune responses. The present review focuses on the various antigen delivery systems that are currently in use and the DC surface receptors they target. (c) 2006 Elsevier GmbH. All rights reserved.
引用
收藏
页码：599 / 608
页数：10
相关论文
共 90 条
[1]   OXIDATIVE REDUCTIVE CONJUGATION OF MANNAN TO ANTIGEN SELECTS FOR T-1 OR T-2 IMMUNE-RESPONSES [J].
APOSTOLOPOULOS, V ;
PIETERSZ, GA ;
LOVELAND, BE ;
SANDRIN, MS ;
MCKENZIE, IFC .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (22) :10128-10132
[2]  
Apostolopoulos V, 2000, EUR J IMMUNOL, V30, P1714, DOI 10.1002/1521-4141(200006)30:6<1714::AID-IMMU1714>3.0.CO
[3]  
2-C
[4]   Liposomal meningococcal B vaccination: Role of dendritic cell targeting in the development of a protective immune response [J].
Arigita, C ;
Bevaart, L ;
Everse, LA ;
Koning, GA ;
Hennink, WE ;
Crommelin, DJA ;
van de Winkel, JGJ ;
van Vugt, MJ ;
Kersten, GFA ;
Jiskoot, W .
INFECTION AND IMMUNITY, 2003, 71 (09) :5210-5218
[5]  
ARNAOUT MA, 1990, BLOOD, V75, P1037
[6]   Dendritic cells [J].
Bell, D ;
Young, JW ;
Banchereau, J .
ADVANCES IN IMMUNOLOGY, VOL. 72, 1999, 72 :255-324
[7]   Genetically targeted adenovirus vector directed to CD40-expressing cells [J].
Belousova, N ;
Korokhov, N ;
Krendelshchikova, V ;
Simonenko, V ;
Mikheeva, G ;
Triozzi, PL ;
Aldrich, WA ;
Banerjee, PT ;
Gillies, SD ;
Curiel, DT ;
Krasnykh, V .
JOURNAL OF VIROLOGY, 2003, 77 (21) :11367-11377
[8]   Rapid monoclonal antibody generation via dendritic cell targeting in vivo [J].
Berry, JD ;
Licea, A ;
Popkov, M ;
Cortez, X ;
Fuller, R ;
Elia, M ;
Kerwin, L ;
Kubitz, D ;
Barbas, CF .
HYBRIDOMA AND HYBRIDOMICS, 2003, 22 (01) :23-31
[9]   Peptides chaperoned by heat-shock proteins are a necessary and sufficient source of antigen in the cross-priming of CD8+ T cells [J].
Binder, RJ ;
Srivastava, PK .
NATURE IMMUNOLOGY, 2005, 6 (06) :593-599
[10]   Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance [J].
Bonifaz, L ;
Bonnyay, D ;
Mahnke, K ;
Rivera, M ;
Nussenzweig, MC ;
Steinman, RM .
JOURNAL OF EXPERIMENTAL MEDICINE, 2002, 196 (12) :1627-1638
123456789